Globus strengthens position as UK's leading force in hand protection

Published: 5-Mar-2010
Personal Protection Regulatory

Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.

Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.

From 1 March 2010 Globus has taken over all Showabest activities in the UK and Ireland. The addition of unique chemical protection products and the world's most advanced disposable glove offer gives Globus the only product portfolio that can claim the original iconic styles that created totally new markets for their distribution partners.

Grip style gloves, Palm Fit technology, Dyneema cut protective gloves and the world's first and patented disposable nitrile glove were all created by the Showabest organisation.

Innovative sales & marketing techniques have seen Globus rise to the forefront of the hand protection sector. Its customers now look set to enjoy the benefits of an invigorated range supported by UK stock and extensive sales support infrastructure.
See more

You may also like

Regulatory

Biocon Biologics wins FDA approval for Bosaya and Aukelso, denosumab biosimilars to Prolia and Xgeva

Read more
The approvals mark a major step in Biocon’s mission to deliver affordable, high-quality biologics, with Bosaya offering a cost-effective treatment for osteoporosis and Aukelso expanding access to oncology care for patients with bone-related complications

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    From approval to access: the strategic role of packaging in drug launch success In today’s increasingly complex pharmaceutical landscape, securing regulatory approval is only one milestone on the journey to market

Upcoming event

POWTECH

23-25 September 2025 | Exhibition | Nuremberg, Germany See all

You may also like

Regulatory

Biocon Biologics wins FDA approval for Bosaya and Aukelso, denosumab biosimilars to Prolia and Xgeva

The approvals mark a major step in Biocon’s mission to deliver affordable, high-quality biologics, with Bosaya offering a cost-effective treatment for osteoporosis and Aukelso expanding access to oncology care for patients with bone-related complications
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
Subscribe now